IDH1

IDH1

IDH1 분자 정보

Molecule Name
Isocitrate dehydrogenase [NADP] cytoplasmic
분자 별명
IDH1,PICD,IDP
Drug Development Progress
임상 약물 수11
시판 약물 수3
최고 연구 개발 단계Approved
표적 별명
IDH,EC 1.1.1.42,PICD,IDCD,Isocitrate Dehydrogenase (NADP(+)) 1,Isocitrate Dehydrogenase 1 (NADP+), Soluble,HEL-S-26,IDH1,Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic,HEL-216,NADP(+)-Specific ICDH,Cytosolic NADP-Isocitrate Dehydrogenase,IDP,NADP-Dependent Isocitrate Dehydrogenase, Cytosolic,Oxalosuccinate Decarboxylase,Epididymis Secretory Protein Li 26,Isocitrate Dehydrogenase 1 (NADP+),NADP-Dependent Isocitrate Dehydrogenase, Peroxisomal,IDPC,EC:1.1.1.42,Epididymis Luminal Protein 216,Epididymis Secretory Sperm Binding Protein,Isocitrate Dehydrogenase [NADP] Cytoplasmic
분자 배경
The IDH enzymes catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), producing nicotinamide adenine dinucleotide phosphate (NADPH) in the process via the citric acid cycle. Eukaryotic cells express two distinct classes of IDHs that utilize either NAD or NADP as their cofactors and serve diverse biological functions. NAD-dependent IDH is localized to the mitochondrial matrix and is well known for its central role for energy production in the Krebs cycle. NADP-dependent IDHs are primarily located either in mitochondria or cytoplasm . Each NADP-dependent isozyme is a homodimer. Mutations of Arg132 of human IDH1 result in a reduced ability of the enzyme to convert isocitrate to alpha ‑ketoglutarate, but the enzyme acquires the ability to generate 2-hydroxyglutarate (2HG) from alpha‑ketoglutarate,2-HG is elevated in several tumor types, including a subset of AMLs.

IDH1 제품 목록

Species
  • Human(2)
Tag
  • His Tag(2)
Host
  • E. coli(2)
Conjugate
  • Unconjugated(2)
Grade
  • RUO(2)
Low Endotoxin
  • No(2)
분자Cat. No.Product Name종Host구조순도Activity규격 및 가격
IDH1
Human IDH1 Protein, His Tag (active enzyme, MALS verified)
Human
E. coli
MALSSDS-PAGE
Enzyme

$360.00

20ug
IDH1
Human IDH1 (R132C) Protein, His Tag (MALS verified)
Human
E. coli
MALSSDS-PAGE

$360.00

20ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
SafusidenibDS-1001b; DS-1001; AB-218Phase 3 ClinicalDaiichi Sankyo Co Ltd
Astrocytoma; Biliary Tract Neoplasms; Glioblastoma; Glioma; Oligodendroglioma; Solid tumours
상세
RanosidenibHMPL-306Phase 3 Clinical
Glioma; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Solid tumours
상세
TQB-3454TQB-3454; CT-2755Phase 3 ClinicalBeijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Bile Duct Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Solid tumours
상세
MT-001MT-001; MT001Phase 2 ClinicalZhejiang Meton Pharmaceutical Co Ltd
Neoplasms; Solid tumours
상세
BAY-1436032BAY-1436032Phase 1 ClinicalBayer AG
Leukemia, Myeloid, Acute; Solid tumours
상세
IDH-305IDH-305Phase 1 ClinicalNovartis Pharma Ag
Glioma; Leukemia, Myeloid, Acute; Neoplasms
상세
IDH1/2 inhibitor (Eli Lilly)Phase 1 ClinicalEli Lilly And Company
Neoplasms
상세
BPI-221351BPI-221351Phase 1 ClinicalBetta Pharmaceuticals Co Ltd
Glioma; Solid tumours
상세
KY-100001KY-100001Phase 1 ClinicalKpc Pharmaceuticals Inc
Solid tumours
상세
HH-2301HH-2301; HH2301Phase 1 ClinicalShangHai HaiHe Biopharma Co Ltd
Biliary Tract Neoplasms; Chondrosarcoma; Glioma; Solid tumours
상세
LY-3410738LY-3410738Phase 1 ClinicalEli Lilly And Company
Cholangiocarcinoma; Chondrosarcoma; Glioma; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Solid tumours
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
IvosidenibCS-3010; S-95031; CS 3010; AG-120ApprovedAgios Pharmaceuticals Inc拓舒沃, Tidhesco, Tibsovo, TIBSOVO, Tuoshuvo, TosuvoUnited StatesLeukemia, Myeloid, AcuteServier Pharmaceuticals Llc2018-07-20
Bile Duct Neoplasms; Cholangiocarcinoma; Chondrosarcoma; Ependymoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Medulloblastoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Myeloid; Solid tumours; Wilms Tumor
상세
VorasidenibAG-881; AGI-23088; S-95032; S95032ApprovedAgios Pharmaceuticals IncVORANIGOUnited StatesAstrocytoma; Oligodendroglioma; GliomaServier Pharmaceuticals Llc, Laboratoires Servier2024-08-06
Astrocytoma; Ganglioglioma; Glioblastoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Liver Diseases; Liver Dysfunction; Myelodysplastic Syndromes; Oligodendroglioma
상세
OlutasidenibFT-2102ApprovedForma Therapeutics Holdings IncRezlidhiaUnited StatesLeukemia, Myeloid, AcuteRigel Pharmaceuticals Inc2022-12-01
Chondrosarcoma; Diarrhea; Irritable Bowel Syndrome; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes
상세
Customer Reviews